Angiogenesis
Apoptosis
Autophagy
Cell Cycle
Cytoskeletal Signaling
DNA Damage
Endocrinology&Hormones
Epigenetics
ER stress & UPR
GPCR & G Protein
Immunology&Inflammation
JAK/STAT
MAPK
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
Metabolism
Microbiology
Natural products
Neuronal Signaling
NF-κB
PI3K/Akt/mTOR
Proteases
Protein Tyrosine Kinase
Stem Cells & Wnt
TGF-beta/Smad
Transmembrane Transporters
Ubiquitin
Others
Screening library
Peptide
Enzymes and proteins
Sphingolipids
Amino acid
Carbohydrates
Dyeing and dyes
Nucleotides
Vitamins
Analytical Standards
Drug impurity
Derivative analytical reagent
Chromatographic solvent
Analysis materials
Chiral compounds
Amino acid derivatives
Catalysts and Ligands
Benzene ring compounds
Indole compounds
Pyridine compounds
Other heterocyclic compounds
Other synthetic blocks
Inorganic salt
Proteins and Peptides
Analysis and preparation
Chiral analysis and preparation
Customized synthesis
>
Ponatinib
TL1155-10MG
In-stock
90
- +
TL1155-50MG
270
TL1155-250MG
760
l General Information
Product Name
General description
Ponatinib is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.
Synonym
AP24534
Purity
≥99.0%(HPLC)
CAS Number
943319-70-8
Formula
C29H27F3N6O
Molecular Weight
532.56
Suitability
BioReagent, suitable for cell culture, etc.
l Physical and Chemical Information
Appearance
yellow powder
Solubility(25°C)
DMSO
≥50mg/mL
Ethanol
Very slightly soluble
Water
Insoluble
l Storage
Storage temp.
-20°C
l Precautions and Disclaimer
This product is for R&D use only, not for drug, household, or other uses.
l References
1. http://www.drugbank.ca
2. https://ncit.nci.nih.gov
3. https://www.ncbi.nlm.nih.gov
